| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABHD4 |
| Uniprot No | Q8TB40 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-342 |
| 氨基酸序列 | MADDLEQQSQ GWLSSWLPTW RPTSMSQLKN VEARILQCLQ NKFLARYVSL PNQNKIWTVT VSPEQNDRTP LVMVHGFGGG VGLWILNMDS LSARRTLHTF DLLGFGRSSR PAFPRDPEGA EDEFVTSIET WRETMGIPSM ILLGHSLGGF LATSYSIKYP DRVKHLILVD PWGFPLRPTN PSEIRAPPAW VKAVASVLGR SNPLAVLRVA GPWGPGLVQR FRPDFKRKFA DFFEDDTISE YIYHCNAQNP SGETAFKAMM ESFGWARRPM LERIHLIRKD VPITMIYGSD TWIDTSTGKK VKMQRPDSYV RDMEIKGASH HVYADQPHIF NAVVEEICDS VD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABHD4重组蛋白的3篇代表性文献(部分信息为示例性简化，实际文献请以具体数据库检索结果为准)：
---
1. **文献名称**: *ABHD4 regulates ceramide homeostasis and mitigates neurodegeneration in vivo*
**作者**: Smith J, et al.
**摘要**: 研究通过重组ABHD4蛋白体外实验发现，其具有水解特定神经酰胺的酶活性，并证明其在阿尔茨海默病模型中通过调控神经酰胺代谢减缓神经元凋亡。
---
2. **文献名称**: *Recombinant ABHD4 expression in cancer cells modulates lipid signaling and apoptosis*
**作者**: Lee S, Zhang H.
**摘要**: 利用重组ABHD4蛋白进行功能分析，发现其通过降解促凋亡脂质分子(如N-酰基乙醇胺)抑制卵巢癌细胞增殖，提示其可能作为肿瘤治疗靶点。
---
3. **文献名称**: *Structural characterization of human ABHD4 using recombinant protein technology*
**作者**: Wang Y, et al.
**摘要**: 通过大肠杆菌系统重组表达并纯化ABHD4蛋白，结合X射线晶体学解析其三维结构，揭示了其催化口袋的关键氨基酸残基及潜在抑制剂结合位点。
---
**备注**：以上为基于ABHD4已知生物学功能(脂质代谢、凋亡调控等)的模拟文献示例，真实文献需通过PubMed/Google Scholar检索关键词"ABHD4 recombinant protein"获取。
ABHD4 (α/β-Hydrolase Domain-Containing Protein 4) is a member of the serine hydrolase superfamily, characterized by a conserved α/β-hydrolase fold and catalytic triad (typically Ser-Asp-His). This enzyme is primarily associated with lipid metabolism, particularly in the regulation of bioactive lipid signaling pathways. ABHD4 exhibits lysophospholipase activity, hydrolyzing lysophospholipids like lysophosphatidylcholine (LPC) to generate fatty acids and glycerophospholipid derivatives. Notably, it plays a role in the biosynthesis of N-acyl ethanolamines (NAEs), a class of signaling lipids that interact with cannabinoid receptors and other targets to modulate inflammation, pain, and neuronal functions.
Recombinant ABHD4 protein is produced through heterologous expression systems (e.g., E. coli, mammalian cells, or insect cells) to study its enzymatic properties, substrate specificity, and structural features. Its recombinant form enables precise biochemical characterization, including kinetic assays, inhibitor screening, and structural biology studies (e.g., X-ray crystallography). Research has linked ABHD4 to pathophysiological processes such as cancer progression, neuroinflammation, and metabolic disorders. For example, its dysregulation has been observed in glioblastoma and colorectal cancer, suggesting potential therapeutic targeting. Additionally, ABHD4 knockout studies in mice reveal altered lipid profiles and behavioral phenotypes, highlighting its importance in neurological health.
The development of recombinant ABHD4 tools (antibodies, activity probes, etc.) accelerates drug discovery and mechanistic studies, offering insights into lipid-mediated signaling networks and disease biomarkers. Ongoing research aims to clarify its tissue-specific roles and therapeutic potential in metabolic and neurodegenerative diseases.
×
